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Abstract
OBJECTIVES: The aim of this retrospective multicenter study was to assess how the development of transcatheter aortic valve implant-
ation (TAVI) inﬂuenced the characteristics and outcomes of patients undergoing aortic valve procedures.
METHODS: We reviewed 1395 patients who underwent isolated surgical aortic valve replacement (SAVR) or TAVI in three centres with
a high-volume TAVI programme. Patients were divided into two groups: ‘Pre-TAVI’ (395 patients, 28.3%) and ‘Post-TAVI’ (1000 patients,
71.7%) operated on before and after the introduction of TAVI into clinical practice. We evaluated age, logistic EuroSCORE I (LES) and
hospital mortality according to time periods and the procedure performed, whether SAVR or TAVI.
RESULTS: ‘Post-TAVI’ patients were older (78.2 ± 7.8 vs 76.8 ± 6.7 years; P = 0.002) and with a signiﬁcantly higher LES (17.8 ± 14.7 vs
9.1 ± 9.2%; P < 0.001) than ‘Pre-TAVI’ patients. Hospital mortality was not signiﬁcantly different between groups (‘Pre-TAVI’ vs ‘Post-TAVI’:
2 vs 3.4%; P = 0.17). Of the 1000 ‘Post-TAVI’ patients, 605 (60.5%) underwent TAVI and 395 (39.5%), SAVR. Patients undergoing TAVI were
older (79.9 ± 7.1 vs 75.5 ± 9.2 years; P < 0.001) and with a higher LES (22.9 ± 15.3 vs 9.7 ± 9.3%; P < 0.001) than ‘Post-TAVI’ SAVR patients,
but their hospital mortality was similar (3.9 vs 2.5%; P = 0.22). LES was similar between ‘Pre-TAVI’ and ‘Post-TAVI’ SAVR patients (9.1 ± 9.2
vs 9.7 ± 9.3%; P = 0.26). Furthermore, we did not ﬁnd signiﬁcant differences in the overall hospital mortality between SAVR and TAVI
patients: 2.3 vs 3.9%, P = 0.08.
CONCLUSIONS: This analysis shows that the development of TAVI has caused an increase in the preoperative risk proﬁle of patients
scheduled for aortic valve procedures (SAVR or TAVI) without increasing hospital mortality.
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INTRODUCTION
Surgical aortic valve replacement (SAVR) is the treatment of
choice for severe symptomatic aortic valve stenosis (SSAVS).
A European survey has demonstrated that nearly 30% of patients
suffering from SSAVS were not referred for surgery by their
cardiologist or family physician due to advanced age or severe
comorbidities or were considered inoperable by the cardiac
surgeon and therefore not accepted for SAVR [1]. For this reason,
new therapeutic options for patients with SSAVS were developed
and successfully introduced into clinical practice [2]. Transca-
theter aortic valve implantation (TAVI) provides good clinical and
haemodynamic outcomes both in inoperable patients and in
high-risk elderly patients [3], and during the last few years the
number of procedures, as well as performing centres and per-
forming physicians, has rapidly increased. With TAVI, we are now
treating patients who were not treated in the past, and as a con-
sequence there has probably been a change in the characteristics
of the population of SSAVS patients who undergo a therapeutic
procedure on the aortic valve, whether SAVR or TAVI.
The aim of this retrospective multicenter study was to evaluate
how the introduction and diffusion of TAVI have inﬂuenced
the characteristics and outcomes of patients undergoing aortic
valve procedures and how this change has impacted on aortic
valve surgery programmes.
PATIENTS AND METHODS
We analysed data from 1395 patients who underwent isolated
aortic valve procedures (SAVR or TAVI) from January 2005 to
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November 2011 at three Italian cardiac surgery centres with a
high TAVI volume. TAVI and SAVR data were collected in the in-
stitutional database of each centre and then retrospectively
transferred to an ‘ad hoc’ database speciﬁcally created for this
study. Data were then sent anonymized to the University of
Padova for storage and analysis. Patients were divided in two
groups: ‘Pre-TAVI’, which included 395 (28.3%) patients who
underwent SAVR before the introduction of TAVI in the three
participating centres (2005–07) and ‘Post-TAVI’, which included
1000 (71.7%) patients who received an aortic valve procedure
after the introduction of TAVI (2007–11).
Indication for SAVR was SSAVS deﬁned by an aortic valve area
<0.8 cm2 and mean transaortic gradient >40 mmHg. Indications
for TAVI were as follows: SSAVS; logistic EuroSCORE I (LES) >20%
and Society of Thoracic Surgeons (STS) score >10%; ascending
porcelain aorta. Patients were excluded if their post-procedural
life expectancy was <1 year. We did not consider speciﬁc age
limits for TAVI. Each case was discussed by the local ‘TAVI team’,
which included a cardiac surgeon, an interventional cardiologist
and an anaesthesiologist. In this study, we included transfemoral
and transapical TAVI. All the three centres follow a ‘transfemoral
ﬁrst’ policy and, as a consequence, transapical procedures were
performed only if the transfemoral approach was not feasible
due to narrow and/or calciﬁed aorto-iliac-femoral vessels. TAVI
were performed with the Edwards Sapien and Sapien XT balloon
expandable bioprosthesis (Edwards Lifesciences, Irvine, CA, USA)
and with the CoreValve Revalving system (Medtronic,
Minneapolis, MN, USA). We considered age and LES [4] in the
two groups of patients and evaluated hospital mortality in the
two groups and in patients undergoing SAVR or TAVI. In particular,
LES was recalculated in all patients, and those with incomplete
data that made LES calculation impossible or unreliable were
excluded. All patients gave written informed consent for the pro-
cedure (TAVI or SAVR) as well as for the data collection. This study
was in accordance with the local ethics committees’ guidelines.
Statistical analysis
Continuous data are expressed as means ± one standard devi-
ation. Categorical data are summarized by reporting absolute
frequency distribution and percentage. Categorical variables
were compared using the χ2 test. Student’s t-test (for unpaired
data) or the Mann–Whitney test was used to compare continu-
ous variables, as appropriate. Statistical ﬁndings were considered
signiﬁcant if the critical level was <5% (P < 0.05). Statistical ana-
lysis was performed using SPSS (release 13.0 for Windows,
Chicago, IL, USA).
RESULTS
Preoperative clinical characteristics as well as the type of proced-
ure performed and kind of implanted prosthesis of the two
groups are listed in Table 1.
Post-TAVI vs Pre-TAVI
Patients operated on in the ‘Post-TAVI’ era were older than
‘Pre-TAVI’ patients (78.2 ± 7.8 vs 76.8 ± 6.7 years; P = 0.002) and
with a signiﬁcantly higher risk proﬁle (LES, 17.8 ± 14.7 vs
9.1 ± 9.2%; P < 0.001). However, hospital mortality was 2% (8
patients) in the ‘Pre-TAVI’ group and 3.4% (34 patients) in the
‘Post-TAVI’ group; this difference was not statistically signiﬁcant
(P = 0.17).
SAVR vs TAVI
In the ‘Post-TAVI’ group, 605 (60.5%) patients received a trans-
catheter bioprosthesis and 395 (39.5%) underwent SAVR. Of
these, 378 (62.5%) underwent a transfemoral procedure, while
227 (37.5%) were scheduled for transapical TAVI. Transfemoral
procedures were performed with a CoreValve and with a
Sapien/Sapien XT device in 196 (51.8%) and 182 (48.2%)
patients, respectively. All transapical TAVI were carried out with a
Sapien/Sapien XT valve. Globally, of the 605 TAVI patients of the
‘Post-TAVI’ group, Sapien/Sapien XT and CoreValve bioprostheses
were used in 409 (67.6) and 196 (32.4%) patients, respectively. In
the ‘Post-TAVI’ group, patients undergoing TAVI were signiﬁcantly
older than SAVR patients (79.9 ± 7.1 vs 75.5 ± 9.2 years;
P < 0.001). Furthermore, TAVI patients had a signiﬁcantly higher
LES compared with those undergoing conventional surgery
(22.9 ± 15.3 vs 9.7 ± 9.3%; P < 0.001). In the ‘Post-TAVI’ group, hos-
pital mortality between TAVI and SAVR was similar. In fact, we
observed 24 (3.9%) and 10 (2.5%) deaths in TAVI and in SAVR
patients, respectively (P = 0.22). Interestingly, we did not observe
differences in patients’ risk proﬁle between patients undergoing
conventional aortic valve replacement both in the ‘Pre-TAVI’ and in
the ‘Post-TAVI’ era (9.1 ± 9.2 vs 9.7 ± 9.3%; P = 0.26). If we consider
all 790 patients who underwent SAVR both in the ‘Pre-TAVI’ and in
the ‘Post-TAVI’ period, the observed hospital mortality was 2.3% (18
patients), which is not signiﬁcantly different from the 3.9% mortality
of TAVI patients (P = 0.08). The rate of mortality of patients under-
going SAVR in the ‘Post-TAVI’ era was 2.5% (10 patients) and this
was similar to that of the ‘Pre-TAVI’ period (2%; 8 patients).
DISCUSSION
With this study, our purpose was to analyse how the introduction
of TAVI into clinical practice has changed the characteristics of
Table 1: Preoperative age and logistic EuroSCORE of the
two study populations and characteristics of the
performed procedure
Variable Pre-TAVI
(N = 395)
Post-TAVI
(N = 1000)
P-value
Age, years 76.8 ± 6.7 78.2 ± 7.8 0.002
Logistic EuroSCORE I 9.1 ± 9.2 17.8 ± 14.7 <0.001
SAVR, n (%) 395 (100) 395 (39.5) <0.001
TAVI, n (%) 0 (0) 605 (60.5)
TF-TAVI, n (%) 378 (62.5)
TA-TAVI, n (%) 227 (37.5)
Sapien/Sapien XT, n (%) 409 (67.6)
TA-TAVI, n (%) 227 (55.5)
TF-TAVI, n (%) 182 (44.5)
CoreValve (TF only), n (%) 196 (32.4)
SAVR: surgical aortic valve replacement; TAVI: transcatheter aortic
valve replacement; TF: trans-femoral; TA: transapical.
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patients undergoing aortic valve procedures (TAVI and SAVR)
and whether this evolution has had any impact on patients’ out-
comes. The incidence of SSAVS increases with age as a conse-
quence of longer life expectancy. It has been estimated that the
prevalence of aortic valve stenosis (at least moderate) is around
2% between 70 and 80 years of age and that it progressively
increases after 80 years [5]. The treatment of elderly patients may
be challenging due to comorbidities that often increase surgical
risk. TAVI in humans was ﬁrst described by Cribier et al. [6] and
since then it has undergone a rapid diffusion and technical
evolution with promising results [7, 8]. We divided our patients
who received an intervention for the treatment of SSAVS accord-
ing to the era of the procedure whether it was performed
before or after the introduction of TAVI. We observed that, after
the introduction of TAVI, there was a signiﬁcant increase in
patients’ age and risk proﬁle. This was obviously due to the
introduction of TAVI into clinical use. In fact, especially at the be-
ginning of the experience, TAVI was mainly dedicated to elderly
and extremely sick patients whose LES was particularly high. This
policy was supported by international consensus papers [9].
Looking at the ‘Post-TAVI’ data, we observed that the preopera-
tive risk proﬁle of SAVR patients was signiﬁcantly lower than TAVI
patients and, more importantly, there were no changes between
‘Pre-TAVI’ and ‘Post-TAVI’ SAVR patients. In other words, the pre-
operative risk proﬁle of patients scheduled for SAVR has not
changed over time and, in particular, it has not changed after
the introduction of TAVI. What makes the global population risk
increase is therefore the referral of TAVI patients. LES of TAVI
patients of this study was around 23%, and this is consistent with
those reported in other TAVI series [10–12]. Although there was a
signiﬁcant increase in LES between groups, we did not observe
signiﬁcant differences in-hospital mortality of patients undergo-
ing aortic valve interventions between the ‘Pre-TAVI’ era (SAVR
only) and the ‘Post-TAVI’ period (SAVR and TAVI). Thus, according
to our data, the introduction of TAVI has led to performing pro-
cedures on a generally sicker population without a signiﬁcant
worsening of hospital mortality. The progressive changes in the
characteristics of patients suffering from aortic valve disease and
undergoing SAVR have already been described by previous
studies based on the analysis of large patient populations. A pro-
gressive increase in comorbidities and preoperative risk proﬁle
over time was described by a large study based on nearly
110 000 patients who underwent isolated SAVR in North
America. The authors found that, despite these changes, the rate
of observed mortality and major complications like stroke had
improved with time and were quite low [13]. This has been con-
ﬁrmed in a paper by Dunning et al. who analysed the Society
for Cardiac Surgery in the Great Britain and Ireland database in
order to assess changes in patients’ characteristics over time.
They observed a signiﬁcant increase in age and rate of high-risk
patients from 2004 to 2009, but found a signiﬁcant reduction in
mortality that decreased from 4.4% in 2004–05 to 3.7% in 2008–
09 (3.2% for isolated SAVR) [14]. The rate of hospital mortality for
isolated SAVR reported by these two large studies based on na-
tional databases is consistent with that found in our study (2%).
Subramanian et al. also report low mortality (1.3%) and low rate
of complications (stroke, respiratory failure and pacemaker im-
plantation) in 79 high patients screened for TAVI but who ﬁnally
underwent SAVR [15]. This means that aortic valve surgery may
be carried out with excellent outcomes even in high-risk
patients. An interesting result of our study is that overall hospital
mortality was not different between SAVR and TAVI in the
‘Post-TAVI’ era, and moreover, it was not different between all
SAVR (‘Pre-’ and ‘Post-TAVI’) and TAVI, although in this case a
trend towards statistical signiﬁcance was observed. In particular,
it is interesting to observe that, despite high EuroSCORE values,
the mortality of TAVI is remarkably low. A similar result was
found by the OBSERVANT trial investigators, where mortality for
TAVI was 3.8%, although in this study, medium-risk patients were
analysed. [16]. The limitations of our study are mainly related to
the relatively small sample of the population, the participation of
only centres with a high TAVI volume and experience, which
may lead to optimal TAVI outcomes, the small number of vari-
ables that were investigated, which does not allow a comprehen-
sive and global assessment of the characteristics of the examined
population and the unmatched nature of the two groups. In
spite of these several limitations, this is the ﬁrst ‘real world’ ana-
lysis of how the features and outcomes of patients referred to
the ‘aortic team’ for the treatment of SSAVS are changing since
TAVI has been introduced into clinical practice.
In conclusion, according to our data, after the introduction of
TAVI, the risk proﬁle of patients with SSAVS undergoing aortic
valve procedures (TAVI or SAVR) has signiﬁcantly increased, but
outcomes are still excellent. The characteristics of patients sched-
uled for SAVR have not changed over time.
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APPENDIX. CONFERENCE DISCUSSION
Dr W. Gomes (São Paulo, Brazil): You report a large experience and superb
short-term outcomes. But in the appraisal of the two different time periods,
pre- and post-TAVI introduction, a jump to 60% TAVI use in symptomatic
aortic stenosis patients, don’t you think that is far above the usual rate of
high-risk patients in the overall population? Could you better explain this
jump from 0 to 60% use of TAVI in these patients? And do you think, or do
you have data on the intermediate or long-term outcomes to endorse these
early results and utilization? And next is the issue of cost. With this jump, can
your health care system afford this in the event of a more widespread use of
TAVI in the coming years?
Dr D’Onofrio: Actually, we do not have a 60% TAVI incidence in our surgi-
cal population. In fact in this study we included all TAVI patients that were
operated on in the three institutions, but not all the surgical patients. We only
included isolated aortic valve procedures in which we were able to retrieve
all data and to recalculate the logistic EuroSCORE. We are well aware that this
is a limitation of this study. However, we did not ﬁnd any difference in mor-
tality between the pre-TAVI and post-TAVI period, although there was a
majority of TAVI patients included in this cohort. So if we manage to include
all conventional aortic valve procedures, this difference will be even smaller.
So this is an important message of this study.
Your second question was about the long-term outcomes. Actually I don’t
have any data. We did not look at this, because it was pretty hard to retrieve
all this data from the institutional databases of each centre, so we only looked
at 30-day mortality. Anyway, we are now implementing all the databases with
follow-up data, especially for conventional AVR patients. So I hope I will be
able to answer this question in the near future. And actually cost-effectiveness
is a big problem. Fortunately in Italy we don’t have 60% of TAVI procedures.
At the moment we have, at least in these three centres, around 20% of TAVI
out of the total volume of aortic valve procedure patients.
Dr A. Furnary (Portland, OR, USA): Your differences in preoperative risk are
greatly different between surgical and TAVI, and there is a slight difference in
preoperative risk before and after your TAVI programme. What were the dif-
ferences in observed-to-expected mortality rates rather than raw mortality
rates? That would be a better thing to compare rather than raw mortality
rates.
Dr D’Onofrio: Well, that is true. In the study we realized that actually we
are talking about two different patient populations. We have the conventional
aortic valve patients against the TAVI patients that have a much higher risk
than conventional patients. However, despite these big differences, the
observed mortality was quite low. We have to say that these are three high
volume TAVI centres, and there is a very strong cooperation in the TAVI team
as well as patient selection and discussion of cases. So despite the high risk of
these patients, we have only 3.9% mortality.
Dr Furnary: Yes, but what was the observed-to-expected ratio? In other
words, all you have to do is divide the expected EuroSCORE by the observed
and you get an observed-to-expected ratio. That is a much better number
rather than saying, well, we looked at it and compared it.
Dr D’Onofrio: We had a 22.9% logistic EuroSCORE of the TAVI population
versus 3.9% of observed mortality. These are the data.
Dr Furnary: You have to do it on a patient-by-patient basis. That should be
the basis of your analysis.
Dr D’Onofrio: Okay. Thank you for your suggestion. I will do it.
Dr M. Moz (Leipzig, Germany): What is the incidence of pacemaker im-
plantation in the Italian Registry of Transapical Aortic Valve Implantation?
Dr D’Onofrio: We have a 3.5% rate of implantation of permanent pace-
maker in this Registry at the moment out of more than 700 cases.
Dr J. Andreasen (Aalborg, Denmark): Have you seen a decrease in the risk
proﬁle of the TAVI patients over time, or do you expect this to happen?
Dr D’Onofrio: This is a good question. In this paper we included all TAVI
patients since the beginning of this experience in Italy. At the start, we
included very high-risk patients, but now we are changing our mind and we
are no longer including extremely high-risk patients, because we have seen
that the outcomes in these patients are not favourable, even with TAVI. Now
we include high-risk patients, but not extremely high-risk patients. I didn’t
look at this data in this paper, but my feeling is that there is a signiﬁcant de-
crease in risk proﬁle over time.
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